In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 11 and 13-27 without prejudice to their presentation in another application, amend claims 4 and 5, and add new claims 32-41 as follows.

1. (previously presented) A vaccine composition comprising isolated inverted microsomes from an animal cell, or membrane fragments thereof, in association with a heterologous peptide antigen and a protein of the Major Histocompatibility Complex (MHC), wherein said peptide antigen and said protein of the MHC are externally disposed.

2. (original) A composition as claimed in claim 1, in which the microsome is from the endoplasmic reticulum of the cell.

3. (previously presented) A composition as claimed in claim 1, in which the protein of the MHC is from a heterologous source with respect to the cell from which the microsomes are obtained.

4. (currently amended) A composition as claimed in claim 1, in which the composition additionally comprises one or more co-stimulatory molecules or cytokines.

5. (currently amended) A composition as claimed in claim 4, in which the co-stimulatory ~~molecules are selected from~~ molecule is B7 ~~and~~ or the cytokine is IL-2.

6. (previously presented) A composition as claimed in claim 1, in which the antigen is from a viral, bacterial, yeast, fungal, or protozoan origin.

7-27. (canceled).

28. (previously presented) A kit of parts comprising a composition as claimed in claim 1 and one or more cytokines and/or adjuvants in sealed containers.

29. (previously presented) A kit of parts as claimed in claim 28, in which the cytokine is IL-2 or IFNγ.

30. (previously presented) A kit of parts comprising a composition as claimed in claim 1 and one or more cytokines and/or adjuvants for separate, subsequent or simultaneous administration to a subject.

31. (previously presented) A kit of parts as claimed in claim 30, in which the cytokine is IL-2 or IFNγ.

32. (new) A composition comprising isolated inverted microsomes from an animal cell, or membrane fragments thereof, in association with a heterologous peptide antigen and a protein of the Major Histocompatibility Complex (MHC), wherein said peptide antigen and said protein of the MHC are externally disposed.

33. (new) A composition as claimed in claim 32, in which the microsome is from the endoplasmic reticulum of the cell.

34. (new) A composition as claimed in claim 32, in which the protein of the MHC is from a heterologous source with respect to the cell from which the microsomes are obtained.

35. (new) A composition as claimed in claim 32, in which the composition additionally comprises one or more co-stimulatory molecules or cytokines.

36. (new) A composition as claimed in claim 35, in which the co-stimulatory molecule is B7 or the cytokine is IL-2.

37. (new) A composition as claimed in claim 32, in which the antigen is from a viral, bacterial, yeast, fungal, or protozoan origin.

38. (new) A kit of parts comprising a composition as claimed in claim 32 and one or more cytokines and/or adjuvants in sealed containers.

39. (new) A kit of parts as claimed in claim 38, in which the cytokine is IL-2 or IFNγ.

40. (new) A kit of parts comprising a composition as claimed in claim 32 and one or more cytokines and/or adjuvants for separate, subsequent or simultaneous administration to a subject.

41. (new) A kit of parts as claimed in claim 40, in which the cytokine is IL-2 or IFNγ.